Yuh-Shyan Tsai
Overview
Explore the profile of Yuh-Shyan Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai Y, Jou Y, Cheong I, Tung H, Hsu L, Tsai H, et al.
Ecotoxicol Environ Saf
. 2025 Jan;
290:117759.
PMID: 39837010
Phthalate exposure is linked to prostate enlargement through sex hormonal changes and oxidative stress. However, its role and action mechanism in prostate cancer remain unclear. This study examined two patient...
2.
Ye D, Kanesvaran R, Chiong E, Lojanapiwat B, Pu Y, Rawal S, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241293393.
PMID: 39583953
Background: The incidence of prostate cancer (PC) is increasing in Asian countries. The epidemiology of PC, its treatment including the use of novel therapeutic options, impacts on quality of life,...
3.
Hsieh Y, Cheong I, Hsu L, Tsai H, Tzai T, Jou Y, et al.
Mol Clin Oncol
. 2024 Sep;
21(5):86.
PMID: 39347478
Urinary 8-hydroxydeoxyguanosine (8-OHdG) level is an oxidative stress marker in patients with cancer; however, little is currently known about the clinical relevance of urinary 8-OHdG levels in patients with prostate...
4.
Wu K, Cheong I, Lai J, Hu C, Hung K, Chen Y, et al.
Cancer Epidemiol
. 2024 Jan;
89:102536.
PMID: 38281454
Background: To investigate the cancer types and risk factors of secondary primary malignancy (SPM) in patients with upper tract urothelial carcinoma (UTUC) in Taiwan. Methods: Using National Health Insurance Research...
5.
Hu C, Hung C, Chen P, Hsu J, Wang C, Lai M, et al.
Biomedicines
. 2023 Oct;
11(10).
PMID: 37892972
Immunotherapy has emerged as a promising modality for cancer treatment. Dendritic cell immunoreceptor (DCIR), a C-type lectin receptor, is expressed mainly by dendritic cells (DCs) and mediates inhibitory intracellular signaling....
6.
Ku J, Lee L, Lin T, Kikuchi E, Kitamura H, Ng C, et al.
Int J Urol
. 2023 Oct;
31(1):64-71.
PMID: 37800879
Objectives: Multiple clinical practice guidelines, conflicting evidence, and physician perceptions result in variations in risk stratification among patients with non-muscle-invasive bladder cancer (NMIBC). This study aims to describe the extent...
7.
Kikuchi E, Ng C, Kitamura H, Ku J, Lee L, Lin T, et al.
Int J Urol
. 2023 Oct;
31(1):32-38.
PMID: 37795933
Objectives: Examine the understanding of terminologies and management patterns of bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) in six territories in Asia-Pacific. Methods: This study involved two phases: (1)...
8.
Chou L, Hsu C, Yang S, Lee C, Ou Y, Lin K, et al.
Clin Genitourin Cancer
. 2023 May;
21(4):508.e1-508.e10.
PMID: 37183125
Introduction/Background To determine the clinical significance of micropapillary urothelial carcinoma (MPUC) of the upper urinary tract (UTUC) and a potential therapeutic strategy. Patients and Methods A retrospective cohort study was...
9.
Hu C, Su B, Lee Y, Wang C, Yang M, Shen W, et al.
J Biomed Sci
. 2022 Dec;
29(1):104.
PMID: 36471329
Background: Cisplatin-based chemotherapy is the first line of treatment for bladder cancer. However, cisplatin induces muscle wasting associated with NF-κB and cancer cachexia. HOTAIR, an oncogenic long non-coding RNA (lncRNA),...
10.
Tsai Y, Wu T, Ou C, Cheng H, Tzai T, Yang W, et al.
BMC Urol
. 2022 Aug;
22(1):126.
PMID: 35987634
Background: To explore the dynamic changes and effects of radical cystectomy on quality of life in muscle-invasive bladder cancer survivors. Methods: Patients with muscle-invasive bladder cancer were randomly recruited in...